Metabolic Control and the Symptoms/Problems Domain of Kidney Disease-Specific Quality of Life in Patients Receiving Kidney Replacement Therapy
Abstract
BackgroundHealth-related quality of life (HRQoL) is an important outcome in patients with chronic kidney disease (CKD) receiving kidney replacement therapy (KRT), but the relationship between comprehensive metabolic control and the Symptoms/Problems domain of kidney disease-specific HRQoL remains uncertain.
ObjectiveTo evaluate the association between composite metabolic control and the Symptoms/Problems domain of the Kidney Disease Quality of Life-36 (KDQOL-36) in patients with stage 5 CKD receiving KRT, and to explore the relationship between individual metabolic parameters and the continuous Symptoms/Problems score.
Materials and MethodsWe conducted an observational, cross-sectional, analytical study of 177 adults receiving hemodialysis or peritoneal dialysis at a nephrology unit in Chihuahua, Mexico. Metabolic control included blood pressure, glycated hemoglobin (HbA1c), total cholesterol, and triglycerides. Adequate control was defined as achievement of at least three of four study-defined operational thresholds. The KDQOL-36 Symptoms/Problems score was analyzed as a continuous variable and categorized as low, moderate, or high according to the study protocol. Group comparisons, Spearman correlations, Pearson chi-square tests, and ordinal logistic regression were performed.
ResultsAdequate metabolic control was present in 106 patients (59.9%). No, statistically significant association was observed between achievement of at least three of four study-defined operational thresholds and Symptoms/Problems score category ({chi}2=3.983; p=0.137; Cramers V=0.150). None of the individual metabolic parameters differed significantly across Symptoms/Problems score categories or showed significant correlations with the continuous score. In ordinal logistic regression, adequate metabolic control yielded an odds ratio of 1.81 (95% CI: 0.98-3.35; p=0.057) after adjustment for age, sex, time receiving KRT, and KRT modality.
ConclusionsNo, statistically significant association was identified between the operational definition of metabolic control used in this study and the KDQOL-36 Symptoms/Problems domain in patients with stage 5 CKD receiving KRT. The findings support evaluating HRQoL multidimensionally and warrant confirmation in larger longitudinal studies.
CategoriesFamily/General Practice, Internal Medicine, Nephrology
Related
- Fulminant Ischemic Colitis With Toxic Megacolon in a Young Man Receiving Testosterone Replacement Therapy Despite Therapeutic Phlebotomy for Hereditary Hemochromatosis: A Case Report
- Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial
- Obesity in Repaired Tetralogy of Fallot: Implications for Symptoms, Right Ventricular Assessment, and Pulmonary Valve Replacement
- Obsessive–Compulsive Personality Disorder Symptoms in Veterans Receiving Posttraumatic Stress Disorder Specialty Care
- Metabolic Abnormalities Among Youths Receiving Antipsychotics Across Different Exposure Periods
BibTeX
@misc{moranramos2026metabolic,
title = {{Metabolic Control and the Symptoms/Problems Domain of Kidney Disease-Specific Quality of Life in Patients Receiving Kidney Replacement Therapy}},
author = {D. Moran-Ramos},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.16.26365777},
url = {https://www.medrxiv.org/content/10.64898/2026.10.16.26365777v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Metabolic Control and the Symptoms/Problems Domain of Kidney Disease-Specific Quality of Life in Patients Receiving Kidney Replacement Therapy
AU - D. Moran-Ramos
PY - 2026
DA - 2026/10/16
PB - medRxiv
DO - 10.64898/2026.10.16.26365777
UR - https://www.medrxiv.org/content/10.64898/2026.10.16.26365777v1
AB - BackgroundHealth-related quality of life (HRQoL) is an important outcome in patients with chronic kidney disease (CKD) receiving kidney replacement therapy (KRT), but the relationship between comprehensive metabolic control and the Symptoms/Problems domain of kidney disease-specific HRQoL remains uncertain. ObjectiveTo evaluate the association between composite metabolic control and the Symptoms/Problems domain of the Kidney Disease Quality of Life-36 (KDQOL-36) in patients with stage 5 CKD receiving KRT, and to explore the relationship between individual metabolic parameters and the continuous Symptoms/Problems score. Materials and MethodsWe conducted an observational, cross-sectional, analytical study of 177 adults receiving hemodialysis or peritoneal dialysis at a nephrology unit in Chihuahua, Mexico. Metabolic control included blood pressure, glycated hemoglobin (HbA1c), total cholesterol, and triglycerides. Adequate control was defined as achievement of at least three of four study-defined operational thresholds. The KDQOL-36 Symptoms/Problems score was analyzed as a continuous variable and categorized as low, moderate, or high according to the study protocol. Group comparisons, Spearman correlations, Pearson chi-square tests, and ordinal logistic regression were performed. ResultsAdequate metabolic control was present in 106 patients (59.9%). No, statistically significant association was observed between achievement of at least three of four study-defined operational thresholds and Symptoms/Problems score category ({chi}2=3.983; p=0.137; Cramers V=0.150). None of the individual metabolic parameters differed significantly across Symptoms/Problems score categories or showed significant correlations with the continuous score. In ordinal logistic regression, adequate metabolic control yielded an odds ratio of 1.81 (95% CI: 0.98-3.35; p=0.057) after adjustment for age, sex, time receiving KRT, and KRT modality. ConclusionsNo, statistically significant association was identified between the operational definition of metabolic control used in this study and the KDQOL-36 Symptoms/Problems domain in patients with stage 5 CKD receiving KRT. The findings support evaluating HRQoL multidimensionally and warrant confirmation in larger longitudinal studies. CategoriesFamily/General Practice, Internal Medicine, Nephrology
ER -